Patients with hepatocellular carcinoma who took statins, in combination with local and systemic treatments or surgical resection, had a 30% lower risk of death than non-statin users. Statin users lived for an average of 25.4 months compared with 18.5 for non-users, researchers said. The retrospective, nonrandomized study, which involved 644 patients, was presented at the Gastrointestinal Cancers Symposium.
Statins linked with lower mortality risk in study of liver cancer
SmartBrief Job Listings for Health Care
Attest Health Care Advisors
|Biotechnology/Pharmaceutical Patent Attorney||
Coats and Bennett PLLC
|Sr. Regulatory Specialist, Biotech Center of Expertise||
BASF, The Chemical Co.
|San Diego, CA|
Meridian Health Plan